BioSpace News Archive

MGI Introduces Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

Most Powerful Sequencer to Date

October 27, 2018
·
2 min read
Drug Development

Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept

October 27, 2018
·
14 min read
Lone Star Bio

Bluegrass Vascular Announces Positive Results From Independent Study Building On Growing Body Of Evidence For Clinical Application Of The Surfacer System

Data presented at the 2018 American Society of Nephrology (ASN) Annual Meeting

October 27, 2018
·
3 min read
Biotech Bay

American Academy of Ophthalmology Announces $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Health

Donation paves the way for the world’s first public museum dedicated to vision

October 27, 2018
·
3 min read
Drug Development

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer’s disease using its AMBAR treatment protocol

Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the “Clinical Trials on Alzheimer’s Disease” (CTAD) congress on October 27, 2018 in Barcelona.

October 27, 2018
·
10 min read
BioMidwest

ZEISS Introduces New Advances in Astigmatism Management and Glaucoma Imaging at American Academy of Ophthalmology Annual Meeting

ZEISS Announces U.S. launch of Total Keratometry (TK®) for IOLMaster® 700, FDA Approval of Astigmatism indication for SMILE®, and Advanced Nerve and Glaucoma Imaging (A N G I) Network at AAO

October 27, 2018
·
4 min read
Biotech Beach

Dialysis Industry Sets National Spending Record by Committing $111 Million to Oppose Prop. 8, Protect Billions in Profits - Reports Californians for Kidney Dialysis Patient Protection

More Than Drug Companies’ $110 Million Campaign in 2016

October 27, 2018
·
2 min read
Drug Development

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)

Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ranibizumab for people with wet AMD1

October 27, 2018
·
13 min read